WST IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - WST - West Pharmaceutical Servs ( NYSE:WST )
NEW YORK, June 15, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. WST between February 16, 2023 and February 12, 2025, both dates inclusive ( the "Class Period" ) , of the important ...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema ( HAE ) at the European Academy of Allergy and Clinical Immunology Congress - Intellia Therapeutics ( NASDAQ:NTLA )
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the ...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema ( HAE ) at the European Academy of Allergy and Clinical Immunology Congress
CAMBRIDGE, Mass., June 15, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing ...
IBTA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - IBTA - Ibotta ( NYSE:IBTA )
NEW YORK, June 15, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc.
TradFi's deep liquidity issue is crypto's silent structural risk
Despite crypto's rapid growth and decentralized ideals, its liquidity remains fragmented and fragile - mirroring traditional finance's hidden risks and exposing the market to sudden shocks when sentiment shifts.
What Are Internet Capital Markets? Why Companies Are Launching Meme Coins
Traditional stocks are old news. Now, companies are launching meme coins to fund or market their businesses.
Dupixent® ( dupilumab ) Demonstrated Superiority Over Xolair® ( Omalizumab ) in Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints ...
Dupixent® ( dupilumab ) Demonstrated Superiority Over Xolair® ( Omalizumab ) in Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, June 15, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps ( CRSwNP ) and coexisting asthma.
Press Release: EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study ...
Press Release: EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - Regeneron Pharmaceuticals ( NASDAQ:REGN )
EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
